NAFLD, MAFLD and obesity: brothers in arms?

2022 was a proficuous year in both the nonalcoholic fatty liver disease (NAFLD) and obesity fields. Pharmacological treatment for obesity and NAFLD is moving forward, with the possibility of replacing bariatric surgery, artificial intelligence might help us access the histological effects of new drugs, and there were advances in personalized hepatocellular carcinoma screening in patients with NAFLD.

Automated summary

The year 2022 witnessed significant progress in both the NAFLD and obesity fields. Advancements in pharmacological treatment offer the potential for replacing bariatric surgery, while the application of artificial intelligence helps in evaluating histological effects of new drugs. Moreover, personalized screening for hepatocellular carcinoma in patients with NAFLD has also seen improvement.